Acalabrutinib(Calquence) Monotherapy Active in Waldenstrom Macroglobulinemia in Phase II—More Study Needed

Acalabrutinib(Calquence) Monotherapy Active in Waldenstrom Macroglobulinemia in Phase II—More Study Needed

Led by Dr. Roger G. Owen, St. James’ University Hospital, Leeds, UK, and colleagues recently concluded that for those patients with treatment-naïve or relapsed/refractory Waldrenstrom Macroglobulinemia (WM), a type of non-Hodgkin lymphoma, single-agent acalabrutinib...

Pin It on Pinterest